- [PRESSWIRE] Belgium – 18.09.23 — AbolerIS Pharma (“AbolerIS”), a biopharmaceutical company developing an entirely novel approach to the treatment of chronic autoimmune and inflammatory diseases, today announced a €27.3 million Series A financing led by Caixa Capital Risc and co-led by Sound Bioventures and existing investor Newton Biocapital with participation from SFPI-FPIM, WE, Sambrinvest, Investsud Tech, and Relyens Innovation Santé/Turenne Capital. Proceeds from the financing will enable AbolerIS to accelerate the development of its lead program in clinical trials and explore its effectiveness in additional autoimmune diseases.
- [PRESSWIRE] Czech Republic – 13.09.23 — On the 5th World Gynecologic Oncology Day, patient advocates around the globe will unite to raise awareness about the importance of testing for gynecologic cancers and their risk factors. World GO Day is a unique opportunity to educate people worldwide about the importance of sharing information about symptoms, treatment, prevention and, especially, testing.
- [PRESSWIRE] US – 08.09.23 — At-the-Market fundraise to support Company through several potentially value-creating milestones and beyond…
- [PRESSWIRE] TORONTO, Ontario and CAMBRIDGE, Massachusetts – September 8, 2023 – ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced that Gail Farfel, Ph.D., Chief Executive Officer and Larry Altstiel, M.D., Ph.D., Chief Medical Officer of ProMIS Neurosciences, will present at the upcoming H.C. Wainwright 25th Annual Global Investment Conference on Tuesday, September 12, 2023 at 4:30 p.m. ET in New York, NY.
- [PRESSWIRE] TORONTO, Ontario and CAMBRIDGE, Massachusetts – September 6, 2023 – ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced that Gail Farfel, Ph.D., Chief Executive Officer and Larry Altstiel, M.D., Ph.D., Chief Medical Officer of ProMIS Neurosciences, will present at the upcoming H.C. Wainwright 25th Annual Global Investment Conference on Tuesday, September 12, 2023 at 4:30 p.m. ET in New York, NY.
- [PRESSWIRE] London, UK – 06.09.23 — New research from tech consulting and engineering firm Zühlke reveals that there is huge unmet demand for prescription apps from the NHS across the whole UK population – particularly for prevention of high-volume illnesses where the NHS is struggling to cope with demand, such as depression, anxiety, obesity & diabetes, and cancer.
- [PRESSWIRE] Switzerland – 31.08.23 — greenteg’s CALERA® technology provides temperature tracking in new generation hybrid, health-monitoring wristwatch.
- [PRESSWIRE] Itagüí, Antioquia, Colombia – 30.08.23 — Efraín Antonio Ríos García, a la edad de 113 años y 133 días, se convirtió en el hombre más longevo en toda la historia de Colombia el pasado 15 de agosto. Él ha sido la persona viva más longeva en Colombia después del fallecimiento del Sr. Eusebio Quintero López el 16 de julio de 2023. Según la lista mundial de LongeviQuest, el Sr. Ríos García es la decimocuarta persona viva más longeva en el mundo. Además, es la sexta persona viva más longeva en América.
- [PRESSWIRE] TORONTO, Ontario and CAMBRIDGE, Massachusetts – May 15, 2023 – ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced its first quarter 2023 financial results and recent highlights.
- [PRESSWIRE] TORONTO, Ontario and CAMBRIDGE, Massachusetts – May 8, 2023 – ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for PMN310 for the treatment of AD. PMN310 is a novel monoclonal antibody which is designed to be highly selective for toxic oligomers of amyloid-beta (Aβ) that are believed to be a major driver of AD.
- [PRESSWIRE] Luxembourg – 04.05.23 — B Medical Systems India Pvt Ltd, a subsidiary of B Medical Systems, today announced the inauguration of its state-of-the-art Global R&D and Customer Excellence Centre in Mumbai. The Centre was inaugurated by Shri Gajanan Kirtikar, a Member of Parliament (MP) from Mumbai North West (Lok Sabha constituency), Maharashtra, India and the event was attended by numerous other dignitaries.
- [PRESSWIRE] Vienna, Austria – 02.05.2003 — CEBINA GmbH, Central European Biotech Incubator and Accelerator, today announces the publication of the positive results of a Phase 2 clinical study that tested azelastine nasal spray as a new approach for reducing viral load in the nose of SARS-CoV-2 positive patients in the peer-reviewed journal Scientific Reports (1).
- [PRESSWIRE] TORONTO, Ontario and CAMBRIDGE, Massachusetts – April 24, 2023 – ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced data supporting the receptor of activated C-kinase 1 (RACK1) as a potential target in ALS and frontotemporal lobar degeneration with TPD-43-immunoreactive pathology (FTLD-TDP), and updated preclinical data from the Company’s lead candidate for AD, PMN310. The data were presented in poster presentations on April 23 at the 75th American Academy of Neurology (AAN) Annual Meeting in Boston, MA.
- [PRESSWIRE] TORONTO, Ontario and CAMBRIDGE, Massachusetts – April 10, 2023 – ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for PMN310 for the treatment of AD.
- [PRESSWIRE] PORTUGAL – 24.03.23 — Tonic App launches ChatGPT assistant to support physicians with medical, admin and personal tasks…
- [PRESSWIRE] TORONTO, Ontario and CAMBRIDGE, Massachusetts – March 13, 2023 – ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced an oral presentation and two onsite poster presentations at the upcoming American Academy of Neurology (AAN) Annual Meeting, which will be held on April 22-27, 2023 in Boston, MA. The presentations highlight ProMIS’ broad pipeline of next-generation neurodegenerative disease therapeutics, including data that further characterize lead drug AD candidate, PMN310, as well as preclinical optimization studies of an Alzheimer’s vaccine and data supporting RACK1 as a potential target in amyotrophic lateral sclerosis (ALS).
- [PRESSWIRE] TORONTO, Ontario and CAMBRIDGE, Massachusetts – March 8, 2023 – ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced its full year 2022 financial results and recent highlights.
- [PRESSWIRE] TORONTO, Ontario and CAMBRIDGE, Massachusetts – March 8, 2023 – ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced that Gail Farfel, Ph.D., Chief Executive Officer, will present at the upcoming Oppenheimer 33rd Annual Conference on Monday, March 13, 2023 at 12:30 p.m. ET.
- [PRESSWIRE] VANCOUVER, BRITISH COLUMBIA, CHATHAM, ONTARIO, EDMONTON, ALBERTA and TEL-AVIV, ISRAEL / Executive Business Services / January 13, 2023 – Atlas Global Brands Inc. (“Atlas Global” or the “Company”) (CSE:ATL), a cannabis company operating in Canada and Israel with expertise across the cannabis value chain, announces that today its common shares (“Common Shares”) have commenced trading on the Canadian Securities Exchange (“CSE”), under the ticker symbol “ATL”.
- [PRESSWIRE] VANCOUVER, BRITISH COLUMBIA, CHATHAM, ONTARIO, EDMONTON, ALBERTA and TEL-AVIV, ISRAEL / Executive Business Services / January 13, 2023 – Atlas Global Brands Inc. (“Atlas Global” or the “Company”) (CSE:ATL), a cannabis company operating in Canada and Israel with expertise across the cannabis value chain, announces that today its common shares (“Common Shares”) have commenced trading on the Canadian Securities Exchange (“CSE”), under the ticker symbol “ATL”.
- [PRESSWIRE] VANCOUVER, BRITISH COLUMBIA, CHATHAM, ONTARIO and TEL-AVIV, ISRAEL / Executive Business Services / January 12, 2023 – Atlas Global Brands Inc. (“Atlas Global”) (CSE: ATL), (formerly Silver Phoenix Resources Inc. “Silver Phoenix” CSE: SP), a global cannabis company with expertise across the cannabis value chain, today announced that, through its Israeli subsidiary, signed a binding letter of intent (the “LOI”) at an arm’s length with no finder’s fee, on January 11, 2023, to acquire 51% of the outstanding securities of the following entities (the “Proposed Transaction”):
- [PRESSWIRE] VANCOUVER, BRITISH COLUMBIA, CHATHAM, ONTARIO and TEL-AVIV, ISRAEL / Executive Business Services / January 12, 2023 – Atlas Global Brands Inc. (“Atlas Global”) (CSE: ATL), (formerly Silver Phoenix Resources Inc. “Silver Phoenix” CSE: SP), a global cannabis company with expertise across the cannabis value chain, today announced that, through its Israeli subsidiary, signed a binding letter of intent (the “LOI”) at an arm’s length with no finder’s fee, on January 11, 2023, to acquire 51% of the outstanding securities of the following entities (the “Proposed Transaction”):
- [PRESSWIRE] TORONTO, Ontario and CAMBRIDGE, Massachusetts – November 14, 2022 – ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic misfolded proteins implicated in the development of neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced its third quarter 2022 financial results and recent highlights.
- [PRESSWIRE] TORONTO, Ontario and CAMBRIDGE, Massachusetts – November 14, 2022 – ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic misfolded proteins implicated in the development of neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced its third quarter 2022 financial results and recent highlights.
- [PRESSWIRE] Toronto, Ontario and Cambridge, MA – October 12, 2022 – ProMIS Neurosciences Inc. (Nasdaq: PMN) (TSX: PMN), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic misfolded proteins implicated in the development of neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced that it has closed a fully subscribed private placement of 1,383,755 Units of the Company at a price of US$5.40 per Unit for gross proceeds of US$7,472,277. Each Unit is comprised of one Common Share of the Company and one quarter of one Common Share purchase Warrant. Each full Warrant is exercisable for one Common Share at US$7.50 for a period of five years commencing six months from the closing of the Offering.
- [PRESSWIRE] Toronto, Ontario and Cambridge, MA – October 12, 2022 – ProMIS Neurosciences Inc. (Nasdaq: PMN) (TSX: PMN), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic misfolded proteins implicated in the development of neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced that it has closed a fully subscribed private placement of 1,383,755 Units of the Company at a price of US$5.40 per Unit for gross proceeds of US$7,472,277. Each Unit is comprised of one Common Share of the Company and one quarter of one Common Share purchase Warrant. Each full Warrant is exercisable for one Common Share at US$7.50 for a period of five years commencing six months from the closing of the Offering.
- [PRESSWIRE] TORONTO, Ontario and CAMBRIDGE, Massachusetts – September 13, 2022– ProMIS Neurosciences, Inc. (Nasdaq: PMN) (TSX: PMN), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers, implicated in the development of neurodegenerative diseases, announced today that it has appointed Gail M. Farfel, Ph.D., as Chief Executive Officer, effective September 19, 2022.
- [PRESSWIRE] TORONTO, Ontario and CAMBRIDGE, Massachusetts – September 13, 2022– ProMIS Neurosciences, Inc. (Nasdaq: PMN) (TSX: PMN), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers, implicated in the development of neurodegenerative diseases, announced today that it has appointed Gail M. Farfel, Ph.D., as Chief Executive Officer, effective September 19, 2022.
- [PRESSWIRE] TORONTO, Ontario and CAMBRIDGE, Massachusetts – August 15, 2022 – ProMIS Neurosciences, Inc. (TSX: PMN) (Nasdaq: PMN) (“ProMIS” or the “Company”), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers, implicated in the development of neurodegenerative diseases, today announced its operational and financial results for the three months ended June 30, 2022.
- [PRESSWIRE] TORONTO, Ontario and CAMBRIDGE, Mass. — August 2, 2022 — ProMIS Neurosciences Inc. (Nasdaq: PMN) (TSX: PMN), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers implicated in the development of neurodegenerative diseases, today announced details of its poster presentation at the annual Alzheimer’s Association International Conference (AAIC®) being held from July 31-August 4, 2022 at the San Diego Convention Center, San Diego California and online.
